pMHC-NPs Development for Chronic Inflammatory Disease

Solutions

Online Inquiry

Chronic inflammatory diseases are usually treated by systemic administration of immunosuppressive or anti-inflammatory drugs, but the long-term use of these drugs may have additional toxic effects and limited therapeutic efficacy, therefore, there is an urgent need to develop effective treatments that target specific cells/tissues. The induction of anti-inflammatory responses in cells or tissues by administering effective amounts of pMHC-NPs complexes is a promising alternative therapy.

Creative BioMart can provide development services for this pMHC-NPs complex for anti-inflammatory use, which contains nanoparticles, MHC proteins and associated antigens to enhance the efficacy of current immunosuppressive therapies and will provide innovative solutions for inflammatory diseases.

Anti-inflammatory Treatment of pMHC-NPs

Inflammatory diseases are a group of conditions caused by abnormal immune responses, including inflammatory bowel disease, psoriasis, and rheumatoid arthritis leading to local or systemic inflammation. Auto-reactive immune responses are a major concern in the pathogenesis of various inflammatory diseases, and therefore re-establishing immune tolerance is a major goal in the treatment of such diseases.

A method of inducing an anti-inflammatory response in cells or tissues by administering pMHC-NPs has emerged in response to the need for treatment of inflammatory diseases. The complex contains nanoparticles, MHC proteins and autoantigens, and this therapeutic strategy can induce antigen-specific T cells with regulatory functions, including FOXP3⁺ CD4⁺ CD25⁺ TReg cells and FOXP3^- CD4⁺ CD25^- TR1 cells, in patients in need, which can suppress the inflammatory process.

Our Solutions

Our solution involves methods for the development of antigen-specific pMHC-NPs drugs that specifically target inflammation without compromising systemic immunity.

Drug Composition	Specific Programs
Peptides	Antigens, including fragments and other molecules derived from antigenic species, including but not limited to peptides presented by classical and non-classical MHC molecules, are selected and isolated to complex or couple them to MHC molecules.
MHC molecules	Antigen presentation to T cells is mediated by two distinct classes of molecules, MHC class I and MHC class II, which utilize different antigen processing pathways. After evaluating and determining which MHC molecule is suitable for the inflammatory disease and constructing a suitable MHC class I or II molecule, specific antigens are identified and presented in the MHC molecule. Non-classical MHC molecules are also considered for application.
Nanoparticles	Particulate formulations containing pMHC complexes can be formed by covalent or non-covalent coupling of the complexes to nanoparticles.

pMHC complex and nanoparticle coupling technology. Using linker molecules, including nucleic acid molecules, polymers, copolymers, polymerizable coupling agents, silica, proteins, that are linked to the nanoparticles and also capable of linking to the pMHC complex, the two can be reacted or linked by chemical modification.

Unique Advantages

Highly stable and effective pMHC constructs.
Ability to target regulatory T-cell production.
Ability to down-regulate pro-inflammatory mediators produced by antigen-presenting cells.
Great potential for the treatment of inflammatory diseases.

Creative BioMart offers the development of new inflammatory therapies based on pMHC-NPs capable of addressing complex autoimmune diseases without compromising systemic immunity. For more information on MHC molecules and inflammatory therapies, contact us for more.

Reference

Prosperi, D, et al. "Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases." Seminars in Immunology (2017), 34:61.

For research use only. Not for clinical use.